Published in Nature in February, the study (doi: 10.1038/nature14169) confirms that pancreatic cancer is one of the most complex malignancies to treat. About a quarter of cases, with one particular mutation, should be susceptible to DNA-damaging drugs, such as platinum-based therapeutics and PARP [poly (ADP–ribose) polymerase] inhibitors, said Andrew Biankin, MD, Ph. D., Regius Professor of Surgery and director of the Wolfson Wohl Cancer Research Centre at Scotland’s University of Glasgow. Researchers from the Australian Pancreatic Genome Initiative, part of the International Cancer Genome Consortium, conducted this research.